Oral Cancer News – Page 89 – The Oral Cancer Foundation News Archive

Troisi: Raising age on tobacco purchases would protect Texas children

Source: www.mystatesman.com Author: Catherine Troisi Tobacco products are a known cancer-causing agent and responsible for one in three cancer deaths. Smoking kills more people than alcohol, AIDS, car crashes, illegal drugs, murders and suicides combined — and thousands more die from smoking-related causes such as fires caused by smoldering cigarettes. E-cigarettes, often touted as a safer alternative, have not been well-studied and may contain unknown poisons. We are not protecting our children from this danger. Unlike alcohol sales, where you have to be 21 years to purchase legally, adolescents and young adults 18 and over can purchase tobacco products. While the Texas Legislature wisely raised the age to buy e-cigarettes from 14 to 18 years last year, it’s time to look at raising the legal age for all tobacco products to 21. The problem is not just those age 18 and older smoking. This young legal age to purchase makes it easier for children under age 18 to get access to cigarettes and other products. Each year, 19,000 Texas children under the age of 18 start smoking. In Texas, almost one out of every six high school students smokes — and over their lifetime, half a million Texans who started smoking under age 18 will ultimately die of tobacco-related diseases. Most of us have someone in our family or know someone who has been affected by a tobacco-related disease. A colleague lost both parents and his only sibling as a result of smoking that began when they were teens. Each [...]

Oral Cancer Foundation News Team - A2016-05-14T08:19:16-07:00May, 2016|Oral Cancer News|

California Raises Smoking Age To 21

Source: www.huffingtonpost.comAuthor: Huffington Post Staff The law makes it the second state to raise the minimum age to 21, following Hawaii. SACRAMENTO, Calif. (Reuters) - California will raise the legal age for purchasing tobacco products to 21 from 18 under a bill signed on Wednesday by Democratic Governor Jerry Brown, part of a package of anti-smoking measures that also regulates electronic cigarettes. Under five bills signed into law on Wednesday, California will ban the sale of vaping products or tobacco to anyone under the age of 21, imposing a fine of up to $5,000 against companies that violate the law. “It is long past due for California to update our approach to tobacco,” said Steven Larson, president of the California Medical Association. “There has been an alarming rise in the use of e-cigarettes by teens, putting them at risk for lifelong addiction.” Under the measures, electronic cigarettes will be regulated like traditional ones. That means that wherever cigarettes are banned, such as in restaurants, workplaces and public areas, use of e-cigarettes will also be prohibited. The state will also expand its funding for anti-smoking programs under the bills. Brown stopped short of allowing local counties to impose their own tobacco taxes, noting in his veto message that several proposed new taxes would be placed before voters on the November ballot. *This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2016-05-05T12:59:24-07:00May, 2016|Oral Cancer News|

Checkpoint inhibitors seen to show potential of immunotherapy in several cancer studies

Source: immuno-oncologynews.com Author: Magdalena Kegel Several new checkpoint inhibitors — a class of immunotherapy drugs used in cancer — continue to show beneficial effects in numerous cancer types, according to data presented at the recent American Association for Cancer Research Annual Meeting in New Orleans. Investigated checkpoint inhibitors confirmed earlier results showing evidence of efficacy in melanoma, and also suggested that this class of immunotherapies, which trigger a person’s immune system to attack cancer, might work in patients suffering from certain head and neck cancers. One of the studies, CheckMate-141, exploring the checkpoint blocker nivolumab (Opdivo) in patients with squamous cell carcinoma of the head and neck, was stopped early after 36 percent of the 361 patients survived for one year — an increase of more than 100 percent compared to patients receiving other treatments. Squamous cell carcinoma is usually treated with platinum-based chemotherapy, but the effects are often temporary as the cancer tends to return. Moreover, patients who fail to fully recover after chemotherapy are generally resistant to further treatment. Maura Gillison from Ohio State University, who presented the CheckMate-141 data, said that no effective treatments have been approved for patients with this kind of cancer in over a decade. “I’ve treated head and neck cancers for more than twenty years, and this is the first time I’ve had a drug to go to for patients that have become resistant to first-line treatment,” she said in a press release. Dr. Emma King, a Cancer Research UK-funded head and neck [...]

Oral Cancer Foundation News Team - A2016-05-04T07:55:52-07:00May, 2016|Oral Cancer News|

Baidu Under Investigation After Cancer Patient’s Death

Source: www.fortune.comAuthor: Scott Cendrowski Baidu, the dominant search engine in China, is being investigated by government regulators after social media users criticized the quality of medical ads appearing in its searches. Chinese social media over the weekend gave widespread exposure to the story of Wei Zexi, a young cancer patient whose family pooled together more than $30,000 for his treatments at a government hospital he found through a Baidu search. The hospital marketed an innovative treatment for synovial sarcoma, the rare form of cancer Wei suffered from. Following an unsuccessful treatment and Wei’s death in April, reports spread that the treatment was much less effective than the hospital had advertised. The Cyberspace Administration of China (CAC) sent investigators to Baidu today, according to China’s official Xinhua news agency Baidu has endured criticism recently for similar instances in which dubious medical practices were promoted in paid search results. Analysts have estimated around one quarter of its revenues come from medical and health-care advertisers. “We deeply regret the death of Zexi,” a Baidu spokeswoman said today, adding that the search engine had launched its own internal investigation of the matter. *This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2016-05-03T15:05:07-07:00May, 2016|Oral Cancer News|

Researchers link hepatitis C virus to head and neck cancers

Source: lymphomanewstoday.com Author: Magdalena Kegel A study from The University of Texas MD Anderson Cancer Center shows the hepatitis C infection, previously linked to liver cancer and non-Hodgkin’s lymphoma, is associated with cancers of the head and neck — a finding that could have immediate implications in how hepatitis-infected patients are screened, and how head and neck cancer patients are treated. Hepatitis C affects as many as 1.5 percent of the U.S. population, making it the most common blood-borne disease in the country, with an estimated 3.9 million having the chronic infection. This number skyrockets to a whopping 130 million to 150 million when considering the global population. New antivirals with few side effects have, however, made it possible to cure up to 90 percent of all hepatitis C patients. The study, “Association Between Hepatitis C Virus and Head and Neck Cancers,” was performed at an MD Anderson clinic focusing on the unmet medical needs of patients with hepatitis C. The clinic opened in 2009, and to date remains the only hepatitis-focused clinic among comprehensive cancer centers in the U.S. “Obviously, a hepatitis C infection could impact how patients respond to their cancer therapy. We also realized that many of our hepatitis patients were excluded from clinical trials. Now that many with hepatitis C can be cured, it is important that we first address and potentially cure the virus, so that they can have access to necessary cancer therapy,” said senior author Harrys A. Torres, in a press release. The [...]

Oral Cancer Foundation News Team - A2016-04-27T07:47:24-07:00April, 2016|Oral Cancer News|

BMS gets US breakthrough status for head & neck cancer

Source: pharmatimes.com Author: Selina McKee US regulators have awarded Bristol-Myers Squibb’s immunotherapy Opdivo a breakthrough designation for the potential indication of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The move, which should help expedite the drug’s development and review, comes after preliminary clinical evidence indicated it could offer a substantial survival benefit to patients with the condition who have already received platinum-based therapy. A first look at the data from the Phase III CheckMate-141 trial, stopped early in January 2016 after meeting its primary endpoint of overall survival, showed that patients treated with Opdivo (nivolumab) experienced a 30 percent reduction in the risk of death compared to the investigator’s choice of therapy (methotrexate, docetaxel, or cetuximab), with a median overall survival of 7.5 months versus to 5.1 months. Safety signals were also looking good, with treatment-related adverse events (TRAEs) of any grade occurring in 58.9 percent of patients on Opdivo versus 77.5 percent of patients on investigator’s choice. Grade 3-4 TRAEs were reported in 13.1 percent of patients on Opdivo compared to 35.1 percent taking the investigator's choice, while two drug-related deaths were reported as related to Opdivo (pneumonitis and hypercalcaemia), and one Grade 5 event of lung infection in the comparator arm. The findings are particularly pertinent given the particularly bleak outlook for patients whose disease has progressed after platinum therapy and lack of systemic therapies to improve survival, and thus significant unmet medical need for new options. Head and neck cancer is the [...]

Oral Cancer Foundation News Team - A2016-04-27T07:39:35-07:00April, 2016|Oral Cancer News|

Drug Target in Rare, Lethal Glandular Cancer Discovered

Source: www.dddmag.comAuthor: Yale University Using a novel cell culture approach, Yale Cancer Center researchers have discovered critical vulnerabilities in adenoid cystic carcinoma (ACC), a rare and lethal glandular cancer with a high recurrence rate and few treatment options. The findings, published April 15th in the journal Clinical Cancer Research, offer data that ACC and similar cancers could be treated with already available drugs. ACC most often occurs in the salivary glands but can originate in the breast, trachea, skin, or other sites. Survival rates at five years are close to 90percent but drop significantly after that with just 40percent surviving at 15 years after diagnosis. It is a slow-growing cancer that affects about 1,200 people each year, with few symptoms in early stages. Aside from surgery, there are few treatments for ACC, which until now has proven largely resistant to radiation therapy. It is this resistance that prompted Yale researchers to develop a novel cell culture technique to isolate and study ACC cancer stem cells, known to be the root of tumor growth, aggressiveness, and resistance to chemotherapy and radiation, said co-senior author Sergey Ivanov, research scientist in surgery (otolaryngology). “Within ACC cells, we found the especially aggressive cancer stem cells. As important, we found the Achilles heel of these cells, which is their addiction to NOTCH1, a signaling molecule that helps these cells to survive therapy and multiply,” Ivanov said. “Fortunately, cancer stem cells can be killed by blocking NOTCH1 production.” The similarities between the ACC stem cells and [...]

Charlotte Parker2016-04-21T10:12:16-07:00April, 2016|Oral Cancer News|

FDA Spends $36 Million on Anti-Chewing Tobacco Ad Campaign

Source: www.freebeacon.comAuthor: Elizabeth Harrington Cans of smokeless tobacco sit in the Tampa Bay Rays dugout before a baseball game between the Rays and the Baltimore Orioles, Wednesday, April 14, 2010, in Baltimore. After hounding Major League Baseball and its players union over steroids, Congress now wants the sport to ban smokeless tobacco. (AP Photo/Rob Carr) The Food and Drug Administration is spending $36 million on an anti-chewing tobacco advertising campaign targeted at white male teenagers in the midwest. The federal agency announced Tuesday it is expanding its “Real Cost” anti-tobacco campaign to “educate rural, white male teenagers” and convince them to stop dipping. “Smokeless tobacco use is culturally ingrained in many rural communities,” the FDA said. “For many, it has become a rite of passage, with these teenagers seeing smokeless tobacco used by role models, such as fathers, grandfathers, older brothers, and community leaders.” The campaign will run television, radio, and print advertisements, as well as put up public signs and billboards and post on social media. An FDA spokesperson told the Washington Free Beacon that the total cost for the campaign is $36 million, which will be financed through taxes on tobacco manufacturers. Paid ads will cost $20 million, and the remaining budget will cover “research, strategic planning, creative development, and contract management.” The agency is also partnering with two dozen minor league baseball teams in the midwest that will host anti-chewing tobacco events and feature advertisements from the campaign. “Amplification of messaging from the campaign will [...]

Charlotte Parker2016-04-21T10:03:14-07:00April, 2016|Oral Cancer News|

Chemotherapy + radiation may improve survival for some elderly

Source: journals.lww.com Author: Carlson, Robert H., Oncology Times Because the toxicity of concurrent chemoradiation is greater than radiation therapy alone for definitive head and neck cancer treatment, many clinicians have reservations about offering chemoradiotherapy for elderly head and neck cancer patients. But a new study shows that combining chemotherapy with radiation therapy improves survival rates for those head and neck cancer patients ages 71 to 79 years who have low comorbidity scores and advanced disease stage, with survival rates similar to that of younger patients. The study, which used data from the National Cancer Data Base (NCDB), suggests elderly patients are being underrepresented in prospective clinical trials that have defined standards of care for head and neck cancer. “In the era of improved radiation techniques, improved systemic therapy, and better supportive care, we found that chemoradiotherapy does, in fact, improve survival for a large segment of this population,” said Sana Karam, MD, PhD, Assistant Professor of Radiation Oncology at the University of Colorado School of Medicine in Aurora, and senior author on the study.“ "These findings challenge historical data demonstrating no benefit of chemoradiotherapy for patients older than 70 years,” Karam said. The study was presented at the 2016 Multidisciplinary Head & Neck Cancer Symposium, sponsored by the American Society for Radiation Oncology (ASTRO) and the American Society of Clinical Oncology (ASCO). First author is Arya Amini, MD, a fourth-year resident in the Department of Radiation Oncology at the University of Colorado School of Medicine. Before the meeting, Karam discussed [...]

Oral Cancer Foundation News Team - A2016-04-19T14:49:31-07:00April, 2016|Oral Cancer News|

Hepatitis C Virus strongly linked to head and neck cancer: study

Source: www.techtimes.com Author: Deepthi B, Tech Times People infected with the Hepatitis C virus (HCV), one of the most common blood-borne virus infections, are more prone to developing particular types of head and neck cancer, according to a new study. Researchers from the Univerity of Texas MD Anderson Cancer Center have revealed that HCV-infected people are at a higher risk of developing these cancers by around two to five times more than those without the Hepatitis C infection. "What we are trying to make all understand is that this is an infection that has consequences – and it's an infection we can cure," said Dr. Harrys Torres, lead author and an associate professor of infectious diseases at the university. Torres further explained that the Hepatitis C infection is easily curable and that over 90 percent of the HCV-related cases can be cured without any trouble simply by taking antiviral drugs, although they are expensive. Also, it is recommended that people should ensure timely screenings and appropriate treatment for HCV, as this can considerably prevent the condition from developing in the body. Hepatitis C appallingly affects more than 3.5 million Americans, according to the U.S. Centers for Disease Control and Prevention. Sadly, several of them are not even aware that they are infected with the virus. For the purpose of the study, researchers examined medical records from over 34,500 patients tested for HCV at the cancer center from 2004 to 2014. The researchers discovered that patients suffering from hepatitis C seemed [...]

Oral Cancer Foundation News Team - A2016-04-19T14:31:09-07:00April, 2016|Oral Cancer News|